Volume | 62,295 |
|
|||||
News | - | ||||||
Day High | 2.15 | Low High |
|||||
Day Low | 1.88 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cocrystal Pharma Inc | COCP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.88 | 1.88 | 2.15 | 1.87 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
376 | 62,295 | $ 2.04 | $ 127,043 | - | 1.325 - 3.285 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:18:36 | 7 | $ 2.14 | USD |
Cocrystal Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
21.57M | 10.17M | - | 2.6M | -17.98M | -1.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cocrystal Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COCP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.53 | 2.15 | 1.53 | 1.74 | 35,981 | 0.59 | 38.56% |
1 Month | 1.43 | 2.15 | 1.4196 | 1.66 | 16,651 | 0.69 | 48.25% |
3 Months | 1.38 | 2.15 | 1.35 | 1.54 | 16,276 | 0.74 | 53.62% |
6 Months | 1.87 | 2.15 | 1.325 | 1.62 | 16,970 | 0.25 | 13.37% |
1 Year | 2.65 | 3.285 | 1.325 | 2.13 | 22,236 | -0.53 | -20.00% |
3 Years | 13.68 | 17.88 | 1.325 | 12.55 | 661,803 | -11.56 | -84.50% |
5 Years | 29.16 | 49.20 | 1.325 | 18.86 | 2,049,386 | -27.04 | -92.73% |
Cocrystal Pharma Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). |